Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

November 13th has seen a myriad of significant events throughout history, impacting various spheres such as politics, science ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The acquisition was part of BioNTech's broader oncology strategy, backed by the financial success of its Covid-19 vaccine ...

BioNTech has agreed to acquire biotechnology company Biotheus for $800 million up front and up to $150 million in milestone payments. The German developer of RNA vaccines and immunotherapies said ...

COVID-19 vaccination coverage has progressed unevenly throughout the world. Moreover, 1.01 and 1.43 doses for each person are ...